NCT06995677Phase 2Recruiting

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Study sponsor: Tyra Biosciences, Inc · TYRA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-02Estimated
Enrollment · participants90Estimated
Source updated2026-10-27Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To assess the efficacy of TYRA-300 in LG IR-NMIBC participants Description: Complete response (CR) rate Time frame: at 3 months. After: Measure: To assess the efficacy of TYRA-300 in LG IR-NMIBC participants Description: Complete response (CR) rate at 3 months Time frame: at 3 months.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview